loadpatents
Patent applications and USPTO patent grants for Nielsen; Niels Fisker.The latest application filed is for "tau antisense oligomers and uses thereof".
Patent | Date |
---|---|
Tau Antisense Oligomers And Uses Thereof App 20220143064 - Olson; Richard E. ;   et al. | 2022-05-12 |
Antisense Oligomers Targeting Pcsk9 App 20220025376 - ALB K; Nanna ;   et al. | 2022-01-27 |
Antisense oligomers targeting PCSK9 Grant 11,091,764 - Alb.ae butted.k , et al. August 17, 2 | 2021-08-17 |
Tau antisense oligomers and uses thereof Grant 11,077,132 - Olson , et al. August 3, 2 | 2021-08-03 |
Tau antisense oligomers and uses thereof Grant 10,799,523 - Olson , et al. October 13, 2 | 2020-10-13 |
Antisense Oligomers Targeting Pcsk9 App 20200248186 - Kind Code | 2020-08-06 |
Methods of Selecting Therapeutic Molecules App 20190383797 - OLSON; Richard E. ;   et al. | 2019-12-19 |
Antisense oligomers targeting PCSK9 Grant 10,443,058 - Alb.ae butted.k , et al. Oc | 2019-10-15 |
Methods of treatment using antisense oligomers and conjugates targeting PCSK9 Grant 10,385,342 - Alb.ae butted.k , et al. A | 2019-08-20 |
Manufacture of antisense oligomers and conjugates targeting PCSK9 Grant 10,370,668 - Alb.ae butted.k , et al. | 2019-08-06 |
Methods of Treatment Using Antisense Oligomers and Conjugates Targeting PCSK9 App 20180312847 - ALB K; Nanna ;   et al. | 2018-11-01 |
Manufacture of Antisense Oligomers and Conjugates Targeting PCSK9 App 20180312846 - ALB K; Nanna ;   et al. | 2018-11-01 |
Antisense Oligomers And Conjugates Targeting Pcsk9 App 20180216116 - Albaek; Nanna ;   et al. | 2018-08-02 |
Tau Antisense Oligomers And Uses Thereof App 20180161356 - Olson; Richard E. ;   et al. | 2018-06-14 |
Oligonucleotide conjugates Grant 9,879,265 - Alb.ae butted.k , et al. January 30, 2 | 2018-01-30 |
Lna Oligonucleotides With Alternating Flanks App 20180023081 - HAGEDORN; Peter ;   et al. | 2018-01-25 |
Tau Antisense Oligomers and Uses Thereof App 20160237427 - OLSON; Richard E. ;   et al. | 2016-08-18 |
Oligonucleotide Conjugates App 20160138025 - ALB K; Nanna ;   et al. | 2016-05-19 |
Oligonucleotide Modulators Of B-cell Cll/lymphoma 11a (bcl11a) And Uses Thereof App 20160130582 - HEDTJARN; Maj ;   et al. | 2016-05-12 |
Potent anti APOB antisense compounds Grant 9,290,758 - Nielsen , et al. March 22, 2 | 2016-03-22 |
Short oligomer antagonist compounds for the modulation of target mRNA Grant 8,580,756 - Hansen , et al. November 12, 2 | 2013-11-12 |
Antisense oligomers targeting PCSK9 Grant 8,563,528 - Straarup , et al. October 22, 2 | 2013-10-22 |
Antisense Oligomers Targeting PCSK9 App 20120122954 - Straarup; Ellen Marie ;   et al. | 2012-05-17 |
Pharmaceutical Composition Comprising Anti PCSK9 Oligomers App 20110224280 - Nielsen; Niels Fisker ;   et al. | 2011-09-15 |
Antidote Oligomers App 20110172292 - Hansen; Jens Bo Rode ;   et al. | 2011-07-14 |
RNA Antagonist Compounds for the Modulation of FABP4/AP2 App 20110054011 - McCullagh; Keith ;   et al. | 2011-03-03 |
RNA Antagonist Compounds for the Modulation of PCSK9 App 20100216864 - Straarup; Ellen Marie ;   et al. | 2010-08-26 |
Short RNA Antagonist Compounds for the Modulation of Target mRNA App 20100210712 - Hansen; Jens Bo Rode ;   et al. | 2010-08-19 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.